Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis

Daisuke Koshiyama1, Kenji Kirihara1, Mariko Tada1

  • 1Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Schizophrenia Research
|March 19, 2017
PubMed

Insights

Auditory mismatch negativity (MMN) is a potential biomarker for early psychosis. This study found smaller MMN amplitudes in individuals at high risk or with first-episode psychosis, suggesting a developmental trait rather than progressive decline.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Biomarkers

Background:

  • Auditory mismatch negativity (MMN), an event-related potential, is a candidate biomarker for early psychosis.
  • Previous studies show reduced MMN amplitude in early psychosis, but longitudinal changes are unclear.

Purpose of the Study:

  • To investigate longitudinal changes in MMN amplitude in individuals with first-episode psychosis (FEP) and ultra-high risk (UHR) for psychosis.
  • To determine if reduced MMN amplitude reflects progressive pathology or a stable trait.

Main Methods:

  • Longitudinal MMN assessment in 14 FEP patients, 16 UHR individuals, and 16 healthy controls (HC).
  • MMN measured for duration deviants (dMMN) and frequency deviants (fMMN).
  • Analysis of MMN amplitude changes over the follow-up period.

Main Results:

  • Significantly smaller dMMN amplitudes were observed in FEP and UHR groups compared to HC.
  • dMMN amplitude did not show progressive decrease over time in FEP or UHR groups.
  • fMMN amplitude did not differ between groups and showed no progression.

Conclusions:

  • Reduced dMMN amplitude in early psychosis may represent a stable trait, possibly linked to altered developmental processes.
  • fMMN amplitude appears unaffected in the early stages of psychosis.
  • These findings support dMMN's potential as a biomarker for early psychosis stages.